RMC-6291 is an orally active and covalent inhibitor of KRAS G12C (ON) . RMC-6291 forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA). Thus, RMC-6291 prevents KRAS G12C (ON) from signaling via steric blockade of RAS effector binding. RMC-6291 elicits deep and durable suppression on RAS pathway activity in KRAS G12C tumor modelsForm:SolidIC50& Target:KRAS(G12C).
Specifications and Purity: ≥99%
Molecular Formula: C55H78FN9O8
Molecular Weight: 1012.26
- UPC:
- 12141756
- Condition:
- New
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- R646965-5mg
- CAS:
- 2641998-63-0
- Product Size:
- 5mg
akash.verma@cenmed.com
(732) 447-1115





